Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caligiuri

Showing results (881-890 of 1,066) with videos related to

Pageof 107
Sort By:
Nature Genetics|February 22, 2005
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemiaLi Yu, Chunhui Liu, Jeff Vandeusen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621Jonathan E Kolitz, Stephen L George, Richard K Dodge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphomaKhuda D Khan, Christos Emmanouilides, Don M Benson, et al.
Immunity|May 23, 2006
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cellsJianhua Yu, Min Wei, Brian Becknell, et al.
Journal of Medicinal Chemistry|May 6, 2022
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine DerivativesGiulia Bononi, Miriana Di Stefano, Giulio Poli, et al.
European Journal of Medicinal Chemistry|August 26, 2018
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitorsGiulia Bononi, Carlotta Granchi, Margherita Lapillo, et al.
The Journal of Clinical Investigation|September 19, 2006
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterationsAdrienne M Dorrance, Shujun Liu, Weifeng Yuan, et al.
Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2018
Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and DexamethasoneJames P Dugan, Bradley M Haverkos, Lynda Villagomez, et al.
Blood|December 8, 2009
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibodyFarrukh T Awan, Rosa Lapalombella, Rossana Trotta, et al.
Pageof 107

Showing results (881-890 of 1,066) with videos related to

Sort By:
Pageof 107
Nature Genetics|February 22, 2005
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemiaLi Yu, Chunhui Liu, Jeff Vandeusen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621Jonathan E Kolitz, Stephen L George, Richard K Dodge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphomaKhuda D Khan, Christos Emmanouilides, Don M Benson, et al.
Immunity|May 23, 2006
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cellsJianhua Yu, Min Wei, Brian Becknell, et al.
Journal of Medicinal Chemistry|May 6, 2022
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine DerivativesGiulia Bononi, Miriana Di Stefano, Giulio Poli, et al.
European Journal of Medicinal Chemistry|August 26, 2018
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitorsGiulia Bononi, Carlotta Granchi, Margherita Lapillo, et al.
The Journal of Clinical Investigation|September 19, 2006
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterationsAdrienne M Dorrance, Shujun Liu, Weifeng Yuan, et al.
Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2018
Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and DexamethasoneJames P Dugan, Bradley M Haverkos, Lynda Villagomez, et al.
Blood|December 8, 2009
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibodyFarrukh T Awan, Rosa Lapalombella, Rossana Trotta, et al.
Pageof 107